Alexion's Soliris Adds Prescriber Certification In Move From RiskMAP To REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
The REMS for the hemolysis drug seems to be more onerous than the previous RiskMAP, although the company says there are no new safety problems behind the change.
You may also be interested in...
When To End A REMS? Soliris Review Stirs Debate On How To Scale Back
Risk management program for Alexion’s orphan drug eculizumab appears to be succeeding, but what does FDA need to see to make it less burdensome?
Alexion’s Soliris REMS Working Well But Might Benefit From Small Changes
FDA advisory committee will weigh potential tweaks to orphan drug’s risk management plan, which is meeting informational goals regarding meningococcal infections but could be burdening prescribers with repeated assessments.
The Downside Of REMS: An Over-Taxed Health Care System – FDA’s Jenkins
The increasing number of Risk Evaluation & Mitigation Strategies for drug and biotechnology products could cripple the current health care system - and force an overhaul of the way REMS are administered
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: